ACC.24: Late-Breaking Science Video Collection

Published: 06 April 2024

  • Views:

    Views Icon 4961
  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

Our recurring review series, View from the Thoraxcenter, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offers a thorough examination of late-breaking and featured scientific findings, highlighting significant data.

 

To delve deeper into the pivotal clinical trial data unveiled at ACC 24, Dr Harriette Van Spall (McMaster University, Hamilton, CA) conducts interviews with the principal investigators as part of her Late-Breaker Discussion Series.

 

For brief and focused coverage of the essential data unveiled, our accessible Expert Interviews were conducted with a select group of faculty members, concentrating on the results, relevance, and implications for future research.

 

Watch our Behind the Heart series to learn more the personal perspectives from the investigators behind top trials in cardiovascular science.

More from this programme

Part 1

View from the Thoraxcenter

In these concise episodes of View from the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offer their thoughts on the top late-breaking trials that will be presented at ACC.24. 

Part 2

Late-Breaker Discussion Series

Part 5

Behind the Heart

Watch our Behind the Heart series to learn more the personal perspectives from the investigators behind top trials in cardiovascular science.

About the episode

ACC.24 — We are joined onsite by investigator, Dr Evan A Stein (Medpace Reference Laboratories, US) to discuss the findings from the LIBerate-CVD trial (NCT04797247).

LIBerate-CVD investigated LDL-C reductions in a cohort of 900 patients with cardiovascular diseases and hyper-LDL-cholesterol treated with 300mg subcutaneous Lerodalcibep as compared to placebo across a 52-week treatment period. Lerodalcibep is a small binding protein consisting of an 11kDA anti PCSK9 domain.

Findings showed that Lerodalcibep decreased LDL-C by 56% at week 52 (60.6 mg/dL), and 62% at mean week 50 and week 52 (74.5 mg/dL). The drug was well tolerated, with adverse events similar to that of placebo. On lerodalcibep, high risk CVD patients on maximally tolerated statins achieved both of the more stringent ESC targets for reduction in LDL-C. 

Interview Questions:

  1. What is the rationale behind this study?
  2. Could you tell us about the mechanism of action of lerodalcibep?
  3. What was the patient population and study design?
  4. What are the key findings revealed at ACC.24?
  5. What are your key take-home messages?
  6. What further study is needed, and what are the next steps?

Recorded onsite at the ACC Conference in Atlanta, 2024.

Faculty Biographies

Evan A Stein

View full profile

Comments

You must be to comment. If you are not registered, you can register here.